Please login to the form below

Not currently logged in
Email:
Password:

Merck u-turns on NDA for HIV drug

Merck & Co has said it will not submit a New Drug Application (NDA) to the US FDA for its HIV treatment, vicriviroc, at this time

Merck & Co has said it will not submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its HIV treatment, vicriviroc, at this time.

The company has made the announcement after the drug failed to meet the primary efficacy endpoint in two phase III trials in treatment-experienced HIV-infected patients. These particular trials involved a high percentage of patients who had three or more active drugs in their optimised background therapy regimen.

Vicriviroc was one of the drugs acquired by Merck when it purchased Schering-Plough for $41.4bn last year.

Merck will continue with current phase II trials investigating vicriviroc as a therapy in treatment-naïve HIV-infected patients. In addition, those treatment-experienced patients from the phase III who have responded well to treatment with the drug, will continue to have access to the medicine.

21st January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics